Start a new application to McKinsey, retrieve your draft application(s) or access
or update your online account.
To ensure the security of your profile information, please re-enter your password.
Don’t have an account? Register here.
Register to get full access to our articles and reports, including those by McKinsey
Quarterly and the McKinsey Global Institute, and to subscribe to our newsletters
and e-mail alerts.
Gain full access to articles and reports, including those by McKinsey Quarterly
and the McKinsey Global Institute, and subscribe to our newsletters and e-mail alerts.
Sorry, something went wrong and we cannot reset your password right now. Please
try again later.
Please enter the e-mail address you use to sign into your account.
If your e-mail address is associated with an account in our system, we have sent
you instructions on how to reset your password.
July 2014—Insights from our international survey can help healthcare organizations plan their next moves in the journey toward full digitization.more
June 2014—Many companies target the world’s emerging middle-class consumers. Fewer mirror nonprofit D-Rev, which aims to improve the health and lives of people living on less than $4 a day.more
March 2014—About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.more
February 2014—Unlike deals in many industries, big mergers and acquisitions among pharmaceutical companies generally have resulted in positive returns to shareholders.more
November 2013—In 2012, new-drug approvals by the US Food and Drug Administration hit a ten-year high. Can the pharmaceutical industry make this trend last?more
September 2013—Dramatically changing the sector’s inefficient supply chain may eliminate the dangers posed by counterfeiting and medication errors.more
April 2013—Pharmaceutical R&D suffers from declining success rates and a stagnant pipeline. Big data and the analytics that go with it could be a key element of the cure.more
November 2012—Multinationals are flocking to take advantage of the opportunities, but long-term success is by no means assured.more
August 2012—After years of seeing value destroyed by R&D excesses, biopharmaceutical companies can gain healthier returns—but only if they recognize several new imperatives.more
The material on this page draws on the research and experience of McKinsey consultants and other sources. To learn more about our expertise, please visit the Pharmaceuticals & Medical Products Practice.
The creation of knowledge supports McKinsey’s core mission: helping our clients achieve distinctive, lasting, and substantial performance improvements. We publish our insights and those of external experts to help advance the practice of management and provide leaders with facts on which to base business and policy decisions. Views expressed by third-party authors are theirs alone.